Molecules that bind CD180, compositions and methods of use
Disclosed herein are novel CD180 binding molecules, methods for their identification, and methods for their use.
1. An isolated nucleic acid encoding an anti-CD180 antibody or antigen binding fragment thereof comprising the complete amino acid of SEQ ID NO:2.
2. A recombinant expression vector comprising the nucleic acid of claim 1 .
3. A host cell comprising the recombinant expression vector of claim 2 .
4. A method for producing immunoglobulin, comprising:
(a) culturing the host cell of claim 3 under conditions suitable for expression of the nucleic-acid encoded antibody; and
(b) isolating the antibody from the cultured cells.
5. A method for increasing serum immunoglobulin (Ig) level, comprising administering to a subject in need thereof an amount effective to increase serum Ig levels of an anti-CD180 antibody or antigen binding fragment thereof comprising the complete amino acid of SEQ ID NO:2.
6. A method for plasma protein replacement therapy, comprising administering to a subject in need thereof an amount effective to maintain adequate antibody levels in the subject of an anti-CD180 antibody or antigen binding fragment thereof comprising the complete amino acid of SEQ NO:2.
7. A method for treating a disorder selected from the group consisting of an immune deficiency, hypogammaglobulinemia, autoimmune disease, cancer, graft rejection, hyper-IgM syndrome, and infections, comprising, administering to a subject in need thereof an anti-CD180 antibody or antigen binding fragment thereof comprising the complete amino acid of SEQ ID NO:2, wherein the antibody comprises a human CD180 binding domain and does not possess a functional Fc domain, wherein the amount of antibody administered is effective to treat immune deficiency, hypogammaglobulinemia, autoimmune disease, cancer, graft rejection, hyper-IgM syndrome, and infections.